<DOC>
	<DOCNO>NCT02318368</DOCNO>
	<brief_summary>Phase 2 multicenter , control , randomize , double-blind study evaluate efficacy safety ficlatuzumab versus placebo administer erlotinib subject previously untreated metastatic EGFR-mutated NSCLC BDX004 Positive Label .</brief_summary>
	<brief_title>A Phase 2 , Multicenter , Study Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib Subjects Who Have Previously Untreated Metastatic , EGFR-mutated Non-small Cell Lung Cancer ( NSCLC ) BDX004 Positive Label</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Histologically and/or cytologically confirm primary diagnosis Stage IV NSCLC ( accord American Joint Committee Cancer [ AJCC ] 7th edition lung cancer stag criterion ) . Measurable disease accord RECIST v.1.1 . An EGFR exon 19 deletion and/or exon 21 ( L858R ) substitution mutation . BDX004 Positive Label . Have receive prior systemic chemotherapy , immunotherapy , target therapy , biologic therapy metastatic NSCLC . Subjects may previously treat postoperative adjuvant chemotherapy early stage lung cancer chemo radiotherapy locally advanced disease provide complete least 6 month prior enrollment . No prior EGFR TKI therapy allow stage NSCLC . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Exclusion Criteria History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational agent erlotinib . History known brain metastasis . Prior treatment investigational drug biologic agent within 5 half life prior randomization , investigational device within 2 week prior randomization . Any unresolved toxicity previous radiation therapy . Significant cardiovascular disease , include : Echocardiogram ( ECHO ) multiple gated acquisition ( MUGA ) show leave ventricular ejection fraction le 55 % . Cardiac failure New York Heart Association class III IV . Myocardial infarction , severe unstable angina within 6 month prior randomization . History serious ventricular arrhythmia ( ie , ventricular tachycardia ventricular fibrillation ) . Significant thrombotic embolic event within 3 month prior randomization ( significant thrombotic embolic event include limited stroke transient ischemic attack ) . Any uncontrolled severe cardiovascular disease . History prior malignancy within 3 year prior randomization ( except adequately treat nonmelanoma skin cancer , carcinoma situ breast cervix , superficial bladder cancer , early stage prostate cancer , without evidence recurrence ) . Radiographic evidence interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>